Edition:
India

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

0.76USD
22 Jun 2018
Change (% chg)

$0.01 (+1.51%)
Prev Close
$0.75
Open
$0.76
Day's High
$0.79
Day's Low
$0.76
Volume
64,974
Avg. Vol
43,579
52-wk High
$2.05
52-wk Low
$0.73

Chart for

About

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $23.88
Shares Outstanding(Mil.): 13.92
Dividend: --
Yield (%): --

Financials

  CLRB.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -1.24 -- --
ROI: -103.68 14.84 14.38
ROE: -105.20 16.34 16.08

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage:

10 May 2018

BRIEF-Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer

* CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER

04 Apr 2018

BRIEF-Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

27 Mar 2018

BRIEF-Cellectar Reports 2017 Financial Results

* CELLECTAR REPORTS 2017 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

22 Mar 2018

BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma

* CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA

19 Mar 2018

BRIEF-Cellectar Receives USPTO Notice Of Allowance For Patent Covering Use Of CLR 131 In Multiple Myeloma

* CELLECTAR RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING USE OF CLR 131 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

07 Feb 2018

BRIEF-Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions

* CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING

08 Jan 2018

Earnings vs. Estimates